AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02741687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental insulin (insulin lispro)
Description: Supplemental insulin lispro will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) >240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG > 400 mg/dL; 7-9 units of insulin lispro
Study NCT02741687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Supplemental insulin (insulin aspart)
Description: Supplemental insulin aspart will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) >240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG > 400 mg/dL; 7-9 units of insulin lispro
Study NCT02741687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental insulin (insulin aspart)
Description: Supplemental insulin aspart will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) >240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG > 400 mg/dL; 7-9 units of insulin lispro
Study NCT02741687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Long acting basal insulin (insulin detemir)
Description: Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) >180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~* Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~* Fasting and pre-meal BG between >180-240 mg/dl: increase detemir or glargine dose by 10% every day~* Fasting and pre-meal BG >241 mg/dl: increase detemir or glargine dose by 20% every day~* Fasting and pre-meal BG \<100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight
Study NCT02741687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long acting basal insulin (insulin detemir)
Description: Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) >180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~* Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~* Fasting and pre-meal BG between >180-240 mg/dl: increase detemir or glargine dose by 10% every day~* Fasting and pre-meal BG >241 mg/dl: increase detemir or glargine dose by 20% every day~* Fasting and pre-meal BG \<100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight
Study NCT02741687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Long acting basal insulin (insulin glargine)
Description: Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) >180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~* Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~* Fasting and pre-meal BG between >180-240 mg/dl: increase detemir or glargine dose by 10% every day~* Fasting and pre-meal BG >241 mg/dl: increase detemir or glargine dose by 20% every day~* Fasting and pre-meal BG \<100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight
Study NCT02741687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long acting basal insulin (insulin glargine)
Description: Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) >180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~* Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~* Fasting and pre-meal BG between >180-240 mg/dl: increase detemir or glargine dose by 10% every day~* Fasting and pre-meal BG >241 mg/dl: increase detemir or glargine dose by 20% every day~* Fasting and pre-meal BG \<100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight
Study NCT01067950 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolated Pancreas Transplant
Study NCT01067950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Insulin Therapy
Study NCT04386577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (cholecalciferol)
Description: Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
Study NCT04386577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 (cholecalciferol)
Description: Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
Study NCT04386577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Description: Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
Study NCT04386577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fish oil
Description: Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
Study NCT04184167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: intermittent fasting 4 months before ICSI
Description: women will start intermittent fasting before starting ICSI by 4 months
Study NCT04184167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intermittent fasting 4 months before ICSI
Description: women will start intermittent fasting before starting ICSI by 4 months
Study NCT02379533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Study NCT02379533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Study NCT02355704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure controls were performed
Study NCT02355704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure were performed
Study NCT00339625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low fat, high fiber, high fruit and vegetable eating plan
Description: Participants were randomized to a low fat, high fiber, high fruit and vegetable (intervention arm) or their usual diet (control arm)
Study NCT01221181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Dosage/Frequency: 900 mg IV once a week for 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.
Study NCT02218021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samidorphan
Study NCT02218021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02218021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Study NCT02673112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subthreshold exercise (STEP) with mobile health coaching
Description: Aerobic exercise program performed below the HR threshold that causes symptoms and administered by an RA using mobile health coaching
Study NCT02673112 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light stretching (LS)
Description: Brief daily stretching routine.
Study NCT02673112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light stretching (LS)
Description: Brief daily stretching routine.
Study NCT02061007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimonidazole hydrochloride (Hypoxyprobe™-1)
Description: Prior to surgery, patients will be administered a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
Study NCT02061007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional 18F-FMISO PET scan (18F-fluoromisonidazole)
Description: All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered.
Study NCT02061007 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection of Melanoma Metastases
Description: Participants will undergo surgical resection of melanoma metastases within 16 - 24 hours of consuming oral pimonidazole. Pimonidazole staining will be done on formalin-fixed and paraffin-embedded (FFPE) tissues for pimonidazole analysis. All participants will be contacted 24-72 hours post-surgery to be assessed for any adverse events (AEs) related to surgery, pimonidazole consumption and 18F-FMISO (when applicable).
Study NCT04372589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).~Unfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement.
Study NCT05077189 — intervention group
Intervention type: OTHER
Intervention: Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale
Description: 4 items of the DC/TMD scale were used in this study to evaluate the TMJ disorders.~1. Demographics Survey~2. DC/TMD Symptom Questionnaire (SQ)~3. Graded Chronic Pain Scale (GCPS)~4. Jaw Functional Limitation Scale-20 (JFLS-20)
Study NCT02430792 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Football
Description: The football training will consist of sessions of 20 minutes of warm-up exercises. Followed by 20 minutes dribbling, passing, shooting exercises. Ends with 20 minutes of 5-7 a-side games.
Study NCT00330629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Treatment
Description: Participants in this condition will receive the standard behavioral treatment (SBT) described above. Food tastings will be held at the sessions and will focus on fat modified food products.
Study NCT00330629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SBT+LOV
Description: The focus will be on the elimination of meat products as a means to reduce fat intake.
Study NCT03778255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: 1. Injecting carbon nanoparticles (CNP)\[Not Equipped with near-infrared fluorescent vascular imager\] or CNP combining Indocyanine Green(ICG)\[Equipped with near-infrared fluorescent vascular imager\].~2. Identifying and removing sentinel lymph nodes.~3. Staining all nodes using hematoxylin-eosin staining.
Study NCT00971646 — intervention group
Intervention type: OTHER
Intervention: Micturition diary
Description: On the micturition diary patients are asked to note every void and drink. With every void they are asked to estimate their bladder volume and grade their degree of desire to void.
Study NCT00971646 — intervention group
Intervention type: OTHER
Intervention: Hospital Anxiety and Depression scale
Description: This questionnaire is designed to screen for the presence of a mood disorder.
Study NCT00971646 — intervention group
Intervention type: OTHER
Intervention: EuroQol-5D
Description: This questionnaire grades the health condition of the subject.
Study NCT00971646 — intervention group
Intervention type: OTHER
Intervention: Self-consciousness questionnaire
Description: The questions tap cognitive, emotional, and physical appearance aspects of directing their attention to the self.
Study NCT03176966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Patients will take 400 IU vitamin E nightly for 3 months.
Study NCT03176966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole
Description: Patients will take 0.5mg ropinirole nightly for 3 months.
Study NCT03176966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle cramp survey
Description: Patients will complete a survey of muscle cramp frequency and severity at baseline, 3 months, and 6 months.
Study NCT04125823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game-based physical activity training
Description: Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with a motion sensor (Microsoft) and a 52'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades and types of games will be changed.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay.
Study NCT04125823 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy program
Description: A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay.
Study NCT03988751 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ambulation
Description: Variation in ambulatory intensity.
Study NCT01853228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase1 and Phase 2: decitabine
Description: 20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)
Study NCT01853228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1: cytarabine
Description: 1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose
Study NCT01853228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2: cytarabine
Description: Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)
Study NCT01223911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0151-0000-0000
Description: Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
Study NCT01223911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
Study NCT01635361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Medicine Service
Description: The New Medicine Service is an intervention where patients prescribed a new medicine receive followup consultations with the pharmacist 7-14 days and 14-21 days after receiving the new prescription item
Study NCT00574977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinia virus (vvDD-CDSR)
Description: Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be \< 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u.
Study NCT01769118 — intervention group
Intervention type: DRUG
Intervention: Caffeine
Description: Caffeine will be given according to departmental protocol
Study NCT04561609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous CO2 application
Description: Patients lie on examination tables. Lower extremities of the patients are isolated in a therapeutic wrap (single use, low-density, made from biocompatible polyethylene), sealed at the waist. After this, air is first pumped out of the therapeutic wrap, then the wrap was filled with 99.9% CO2 gas. The therapy lasts for 45 minutes.~Each patient from the study group will receive CO2 therapies - four weeks (meaning 20 CO2 therapies that were performed on workdays only).
Study NCT04561609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Each patient from control group will have therapeutic wrap filled with air instead of CO2. Patients from control group will also receive 20 therapies (4 weeks on workdays only), that will also last 45 minutes.
Study NCT02405637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simulated amniotic fluid 20cc/kg/day enterally
Description: simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.